Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker TNXP · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Dis… NCT07621237 · Major Depressive Episode (MDE), Major Depressive Disorder (… TNX-102 SL, Placebo sublingual tablet | TNXP Tonix Pharmaceuticals, Inc. | Phase 2 | Recruiting | 360 | Feb 2028 | Registry ↗ |
| Mar 16, 2026 | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to… NCT07473752 · Phase 1 First-in-human Study Involving Healthy Subjects TNX-1500, Placebo: USP 0.9% sterile saline for injection | TNXP Tonix Pharmaceuticals, Inc. | Phase 1 | Completed | 26 | Feb 22, 2024 | Registry ↗ |
| Mar 11, 2026 | A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality,… NCT07464535 · Healthy Subjects (HS) TNX-102 SL | TNXP Tonix Pharmaceuticals, Inc. | Phase 1 | Completed | 20 | Apr 30, 2022 | Registry ↗ |
| Feb 17, 2026 | A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102… NCT07413367 · Pharmakokinetic, Open Label TNX-102 SL Tablet | TNXP Tonix Pharmaceuticals, Inc. | Phase 1 | Active, not recruiting | 50 | Feb 10, 2026 | Registry ↗ |
| Jun 24, 2025 | Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxicat… NCT06045793 · Cocaine Use, Cocaine Intoxication TNX-1300 (Injection), Placebo (Injection) | TNXP Tonix Pharmaceuticals, Inc. | Phase 2 | Terminated | 3 | Apr 21, 2025 | Registry ↗ |
| Feb 25, 2025 | A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine NCT05679908 · Chronic Migraine, Chronic Migraine, Headache TNX-1900, Placebo Nasal Spray | TNXP Tonix Pharmaceuticals, Inc. | Phase 2 | Completed | 88 | Oct 8, 2023 | Registry ↗ |
| Feb 25, 2025 | Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime… NCT02829814 · Fibromyalgia, Myofascial Pain Syndromes TNX-102 SL Tablet, 2.8 mg, Placebo SL Tablet | TNXP Tonix Pharmaceuticals, Inc. | Phase 3 | Terminated | 51 | Sep 13, 2016 | Registry ↗ |
| Feb 20, 2025 | A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients NCT02589275 · Primary Fibromyalgia TNX-102 SL Tablet 2.8 mg | TNXP Tonix Pharmaceuticals, Inc. | Phase 3 | Completed | 375 | Sep 28, 2016 | Registry ↗ |
| Feb 17, 2025 | Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder… NCT05686408 · Depression, Depressive Disorder TNX-601 ER, Placebo | TNXP Tonix Pharmaceuticals, Inc. | Phase 2 | Completed | 132 | Sep 29, 2023 | Registry ↗ |
| Feb 7, 2025 | A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patient… NCT02436096 · Fibromyalgia, Myofascial Pain Syndromes TNX-102 SL Tablet, 2.8mg, Placebo SL Tablet | TNXP Tonix Pharmaceuticals, Inc. | Phase 3 | Completed | 519 | Sep 2016 | Registry ↗ |
| Feb 6, 2025 | A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD NCT03841773 · PTSD TNX-102 SL, Placebo SL Tablets | TNXP Tonix Pharmaceuticals, Inc. | Phase 3 | Terminated | 192 | Apr 24, 2020 | Registry ↗ |
| Feb 6, 2025 | 12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients NCT03110575 · PTSD TNX-102 SL | TNXP Tonix Pharmaceuticals, Inc. | Phase 3 | Terminated | 190 | Jul 27, 2018 | Registry ↗ |
| Feb 6, 2025 | Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and R… NCT02421679 · PTSD TNX-102 SL | TNXP Tonix Pharmaceuticals, Inc. | Phase 2 | Completed | 159 | May 26, 2016 | Registry ↗ |
| Feb 5, 2025 | A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD NCT03508700 · PTSD TNX-102 SL 5.6 mg | TNXP Tonix Pharmaceuticals, Inc. | Phase 3 | Completed | 93 | Sep 30, 2019 | Registry ↗ |
| Jan 22, 2025 | A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibr… NCT05273749 · Fibromyalgia TNX-102 SL Tablet, 5.6 mg, Placebo SL Tablet | TNXP Tonix Pharmaceuticals, Inc. | Phase 3 | Completed | 457 | Nov 14, 2023 | Registry ↗ |
| Nov 26, 2024 | A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain… NCT05472090 · Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19 TNX-102 SL, Placebo SL Tablet | TNXP Tonix Pharmaceuticals, Inc. | Phase 2 | Completed | 63 | Jul 12, 2023 | Registry ↗ |
| Nov 6, 2024 | Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens NCT05216510 · Detection of Delayed-type Hypersensitivity Reactions to SAR… TNX-2110, TNX-2120 | TNXP Tonix Pharmaceuticals, Inc. | Phase 1 | Terminated | 9 | Sep 17, 2022 | Registry ↗ |
| Jun 20, 2024 | Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditio… NCT02277704 · PTSD TNX-102 SL, Placebo | TNXP Tonix Pharmaceuticals, Inc. | Phase 2 | Completed | 245 | May 2016 | Registry ↗ |
| May 22, 2024 | Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD NCT03062540 · PTSD TNX-102 SL, Placebo SL Tablet | TNXP Tonix Pharmaceuticals, Inc. | Phase 3 | Terminated | 358 | Jul 27, 2018 | Registry ↗ |
| Dec 18, 2023 | A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia NCT04508621 · Fibromyalgia TNX-102 SL, Placebo SL Tablet | TNXP Tonix Pharmaceuticals, Inc. | Phase 3 | Completed | 514 | Nov 1, 2021 | Registry ↗ |
| Dec 11, 2023 | Safety and Efficacy Study of TNX-102 SL in Participants With PTSD NCT05372887 · PTSD TNX-102 SL, Placebo | TNXP Tonix Pharmaceuticals, Inc. | Phase 2 | Withdrawn | 0 | Nov 8, 2022 | Registry ↗ |
| Aug 8, 2022 | A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia NCT04172831 · Fibromyalgia TNX-102 SL, Placebo SL Tablet | TNXP Tonix Pharmaceuticals, Inc. | Phase 3 | Completed | 503 | Oct 29, 2020 | Registry ↗ |
| Jun 29, 2022 | An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Ca… NCT04996056 · Cocaine Intoxication TNX-1300, Usual Care | TNXP Tonix Pharmaceuticals, Inc. | Phase 2 | Withdrawn | 0 | Jun 16, 2022 | Registry ↗ |
| Jan 6, 2020 | Dose-Proportionality and Food Effect Study of TNX-102 SL NCT04164719 · Healthy Subjects TNX-102 SL | TNXP Tonix Pharmaceuticals, Inc. | Phase 1 | Completed | 16 | Dec 24, 2019 | Registry ↗ |
| Sep 11, 2019 | A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg… NCT01490788 · Healthy Treatment A, Treatment B | TNXP Tonix Pharmaceuticals, Inc. | Phase 1 | Completed | 30 | Dec 30, 2011 | Registry ↗ |
| Jul 11, 2019 | Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers. NCT03168022 · Healthy Adults Treatment A, Treatment B | TNXP Tonix Pharmaceuticals, Inc. | Phase 1 | Completed | 43 | Jan 26, 2016 | Registry ↗ |
| Apr 24, 2018 | Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules NCT03443960 · Healthy Subjects TNX-102 SL 5.6 mg, Amrix 30 mg | TNXP Tonix Pharmaceuticals, Inc. | Phase 1 | Completed | 60 | Apr 9, 2018 | Registry ↗ |
| Jul 7, 2017 | 12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients NCT02015234 · Primary Fibromyalgia TNX-102 SL | TNXP Tonix Pharmaceuticals, Inc. | Phase 3 | Completed | 158 | Aug 2015 | Registry ↗ |
| Apr 11, 2017 | Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache NCT02423408 · Tension-Type Headache TNX-201, Placebo | TNXP Tonix Pharmaceuticals, Inc. | Phase 2 | Completed | 165 | Feb 2016 | Registry ↗ |
| Dec 23, 2016 | BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) NCT01903265 · Primary Fibromyalgia TNX-102 SL 2.8mg, Placebo | TNXP Tonix Pharmaceuticals, Inc. | Phase 2/3 | Completed | 205 | Jul 2014 | Registry ↗ |
| May 17, 2016 | Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy Volunteers NCT02290379 · Healthy TNX-201 35 mg, TNX-201 70 mg | TNXP Tonix Pharmaceuticals, Inc. | Phase 1 | Completed | 27 | May 2015 | Registry ↗ |
31 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:33 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances